Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

This publication has 43 references indexed in Scilit:

• Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
  International Journal of Cancer, 2018
• Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
  Breast Cancer Research and Treatment, 2017
• Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
  The Breast, 2016
• The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
  The Lancet Oncology, 2015
• Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
  Breast Cancer Research and Treatment, 2013
• Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
  The Lancet Oncology, 2012
• Increase in response rate by prolonged treatment with neoadjuvant letrozole
  Breast Cancer Research and Treatment, 2008
• Letrozole in the neoadjuvant setting: the P024 trial
  Breast Cancer Research and Treatment, 2007
• Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer
  Cancer, 2007
• Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer
  Cancer, 2006